Stocktoria
TELA Bio, Inc. TELA
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2019-11-08
TELA Bio, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 67.7% | 67.1% | 68.6% | 65.3% | 63.9% |
| Operating margin | -42.0% | -49.2% | -75.4% | -94.2% | -100.0% |
| Net margin | -48.4% | -54.6% | -79.8% | -106.9% | -112.9% |
| FCF margin | -35.7% | -61.4% | -70.9% | -100.5% | -105.4% |
| Return on assets | -47.7% | -43.7% | -59.8% | -65.3% | -53.2% |
| Return on equity | -615.1% | -133.0% | -247.1% | -309.7% | -165.6% |
| Debt / equity | 8.82× | 1.45× | 2.15× | 2.79× | 1.57× |
| Current ratio | 4.20 | 5.01 | 4.23 | 5.03 | 5.58 |
| Revenue growth | 15.8% | 18.6% | 41.1% | 40.6% | 61.8% |
Source: SEC EDGAR filings · CIK 0001561921 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.